Crispr Therapeutics AG (CRSP) - Total Assets
Based on the latest financial reports, Crispr Therapeutics AG (CRSP) holds total assets worth $2.73 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Crispr Therapeutics AG - Total Assets Trend (2014–2025)
This chart illustrates how Crispr Therapeutics AG's total assets have evolved over time, based on quarterly financial data. Also see CRSP market cap for the company's overall valuation and market capitalisation.
Crispr Therapeutics AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Crispr Therapeutics AG's total assets of $2.73 Billion consist of 87.7% current assets and 12.3% non-current assets. Review CRSP liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Crispr Therapeutics AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CRSP stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crispr Therapeutics AG's current assets represent 87.7% of total assets in 2025, an increase from 63.4% in 2014.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2025, down from 61.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 33.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Crispr Therapeutics AG Competitors by Total Assets
Key competitors of Crispr Therapeutics AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Crispr Therapeutics AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.96 | 15.64 | 26.23 |
| Quick Ratio | 17.96 | 15.64 | 26.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.31 Billion | $1.75 Billion | $2.52 Billion |
Crispr Therapeutics AG - Advanced Valuation Insights
This section examines the relationship between Crispr Therapeutics AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.91 |
| Latest Market Cap to Assets Ratio | 2.21 |
| Asset Growth Rate (YoY) | 1.0% |
| Total Assets | $2.27 Billion |
| Market Capitalization | $5.00 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Crispr Therapeutics AG's assets at a significant premium (2.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Crispr Therapeutics AG's assets grew by 1.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Crispr Therapeutics AG (2014–2025)
The table below shows the annual total assets of Crispr Therapeutics AG from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.27 Billion | +1.04% |
| 2024-12-31 | $2.24 Billion | +0.56% |
| 2023-12-31 | $2.23 Billion | -0.60% |
| 2022-12-31 | $2.24 Billion | -18.49% |
| 2021-12-31 | $2.75 Billion | +50.54% |
| 2020-12-31 | $1.83 Billion | +71.36% |
| 2019-12-31 | $1.07 Billion | +118.14% |
| 2018-12-31 | $489.02 Million | +80.22% |
| 2017-12-31 | $271.35 Million | -21.34% |
| 2016-12-31 | $344.96 Million | +116.38% |
| 2015-12-31 | $159.42 Million | +10340.28% |
| 2014-12-31 | $1.53 Million | -- |
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of … Read more